The epidermal-growth-factor-receptor- (EGFR-) driven pathways seem to affect the growth and behavior of a significant number of solid tumors. Monoclonal antibodies to EGFR and small-molecule inhibitors of the tyrosine kinase activity of the EGFR receptor are two classes of anticancer agents that inhibit EGFR. Anti-EGFR monoclonal antibodies therapies have been approved in the treatment of several types of solid tumors such as squamous cell carcinoma of the head and neck (SCCHN), colorectal cancer, and breast cancer and have been extensively studied in other malignancies such as lung cancer and esophageal cancer.

We invite investigators to contribute original research articles as well as review articles that will cover preclinical studies exploring EGFR signaling and mechanisms of resistance and using EGFR monoclonal antibodies. Review papers covering the optimal use of these agents in treating a variety of solid tumors are also welcome. Potential topics include, but are not limited to:

• The epidermal growth factor receptor: the rationale for targeting and treatment strategies
• Monoclonal antibodies to EGFR: preclinical models
• Monoclonal antibodies to EGFR: phase I studies
• Monoclonal antibodies to EGFR: studies in lung cancer
• Monoclonal antibodies to EGFR: studies and guidelines in squamous cell carcinoma of the head and neck cancer
• Mechanisms of resistance to EGFR antibodies
• Monoclonal antibodies to EGFR: applications in colorectal cancer
• Monoclonal antibodies to EGFR: studies in breast cancer
• Overview of anti-Her-2 therapy: present and future
• Molecular predictors of response to EGFR monoclonal antibodies and future strategies

Before submission authors should carefully read over the journal's Author Guidelines, which are located at http://www.hindawi.com/journals/chrp/guidelines/. Prospective authors should submit an electronic copy of their complete manuscript through the journal Manuscript Tracking System at http://mts.hindawi.com/ according to the following timetable: